Annual Event Brandishes the Next Generation of Clinicians and Scientists
A year after hundreds of high school, undergraduate, and graduate students were only able to participate from afar in NIH’s 2021 Summer Internship Program, IRP researchers were excited to welcome some of the program’s 2022 participants to campus. Regardless of whether they were working in the lab or remotely, these budding scientists received a full-time immersion into the world of IRP science and, surely, learned a great deal from the mentorship of NIH’s many world-renowned researchers.
To celebrate the interns’ hard work, NIH’s Summer Poster Days on August 3 and 4 gave more than 600 of them the opportunity to virtually present posters explaining their projects. With so many bright young men and women displaying the fruits of their scientific labors, it was difficult to select just a handful to highlight in this blog. Read on to learn about how five of NIH’s 2022 summer interns shed light on topics from the microbes living on our skin to the blood-clotting platelets that flow through our veins.
Results Suggest Dual Functions for Memory-Related Brain Area
Scientists studying memory have been closely scrutinizing a brain structure called the hippocampus ever since a man named Henry Molaison — better known as ‘patient H.M.’ — lost his ability to create new memories after surgeons removed that portion of his brain as a last-ditch treatment for his unrelenting epileptic seizures. For the most part, that research has treated the hippocampus as one homogenous structure. However, a recent IRP study lends support to the growing recognition that recall is a multi-stage process in which different parts of the hippocampus play different roles.
IRP’s Mary Carrington Elected to the American Academy of Arts and Sciences for Insights Into Immune System Variations
Some people never seem to get sick, while others catch a new bug of some sort every other week. Humans are immensely variable both in their capacity to shrug off illness and in the ways their bodies respond to medical treatments. IRP senior investigator Mary Carrington, Ph.D., has spent her entire career exploring the biological roots of these differences, and the discoveries she has made earned her election to the American Academy of Arts and Sciences earlier this year.
Genetically Modified Insects Could Help Curb Infections
“Scientists create genetically modified mosquitos” sounds like the plot of a bad sci-fi movie, but it’s actually the reality in labs all around the world. Researchers are producing these ‘transgenic’ mosquitos in the hopes that the bugs could help combat the scourge of malaria, and in a recent study, IRP scientists demonstrated that theirunique strategy in this realm has strong potential to accomplish that goal.
Government Awards Recognize H. Clifford Lane’s Four Decades of Research Achievements
The remarkable career of H. Clifford Lane, M.D., might have gone very differently if a NIH scientist hadn’t accidentally eavesdropped on Dr. Lane’s conversation with a colleague in 1979. After hearing Dr. Lane mention that he had missed the deadline to apply for a position at NIH, the NIH researcher made some calls and discovered a spot there had just opened up — one that was perfect for Dr. Lane, who would spend the ensuing decades conducting life-saving research to understand and combat some of the world’s most dangerous infectious diseases.
Now the Clinical Director at the National Institute for Allergy and Infectious Disease (NIAID), Dr. Lane has been named a finalist for the 2022 Samuel J. Heyman Service to America Medals’ Career Achievement Award in recognition of his crucial contributions to the fight against HIV/AIDS, Ebola, COVID-19, and other illnesses. Also known as the “Sammies,” the awards recognize federal employees who are “breaking down barriers, overcoming huge challenges, and getting results.”
IRP Study Could Help Explain Racial Disparities in Disease Outcomes
Even as advances in therapy are extending the lives of many cancer patients, there are still stark differences in how likely patients of different races and ethnicities are to die from the disease. A recent IRP study suggests that a weaker immune response against cancer could explain the worse clinical outcomes for Black men with prostate cancer, pointing to potential strategies that could help close this gap.
IRP Researchers Engage and Educate at Competition Finals
English is generally considered the ‘international language of science,’ since nearly all scientific papers are published in English. Yet, even to a native English speaker, scientists seem to be using another language entirely to talk about their research. Most Americans, after all, don’t know an ‘autophagosome’ from a ‘lysosome’ and would be hard-pressed to explain the difference between an ‘oocyst’ and a ’sporozoite.’
Fortunately, efforts like NIH’s annual Three-Minute Talks (TmT) competition are helping scientists learn how to communicate about their research in a manner that is much easier to understand. On June 30, after months spent whittling down dozens of competitors from across the IRP, 10 finalists raced against the clock to explain their work and its importance in a clear and compelling way.
Study Reveals Medications Associated With Lower Odds of Severe Infection
Many researchers studying COVID-19 have spent the past two years poring over test tubes and isolated cells. However, large troves of data about people’s interactions with the healthcare system can also be a rich source of useful insights. Using one such database, IRP researchers found that older adults taking certain medications were less likely to catch COVID or experience severe repercussions from the virus.
Dr. Stefan Barisic Turns Laboratory Discoveries into Kidney Cancer Treatments
The Laboratory of Transplantation Immunotherapy sits at the heart of the NIH Clinical Center, just down the hallway from the Southeast inpatient unit. Here, IRP postdoctoral research fellow Stefan Barisic, M.D., labors at the bench with the goal of creating practical treatments for kidney cancer patients. Having such proximity to his patients was one of the chief attractions of working at NIH for Dr. Barisic.
“The NIH Clinical Center is an amazing place because it has all the resources you need to go from the bench to the bedside and back to the bench all in one building,” says Dr. Barisic.
Drug Candidate Could Slow Progression and Reduce Side Effects
If you know someone with Parkinson’s disease, you’re probably familiar with the progressive tremors and movement difficulties it causes. Unfortunately, the most common treatment for the disease — a drug called levodopa, or L-DOPA for short — can make some movement problems worse when taken for long periods of time. That’s why IRP senior investigator David R. Sibley, Ph.D., and postdoctoral fellow Amy Moritz, Ph.D., have taken on the challenge of discovering new drugs that could be given to patients in conjunction with existing treatments to more effectively slow the disease’s progression while reducing side effects.
This page was last updated on Friday, January 14, 2022
